Research map: Sociodemographic and Clinical Factors Associated With Nirsevimab Receipt Among Children Aged Younger Than 20 Months in the New Vaccine Surveillance Network in 2023 to 2025

Back to the article

Papers in this map

  1. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 · Jefferson M. Jones · 2023 · 368 citations · Cited by this paper
  2. Collaborative and Empathetic Communication as a Critical Tool to Build Rapport and Engage Families in Family-Centered Rounds · 2026 · Related
  3. Respiratory Virus Surveillance Among Children with Acute Respiratory Illnesses — New Vaccine Surveillance Network, United States, 2016–2021 · Ariana Perez · 2022 · 143 citations · Cited by this paper
  4. The Essential Role of Pediatric Trainees in Developing Ethical Artificial Intelligence Tools · 2026 · Related
  5. Early-life respiratory syncytial virus disease and long-term respiratory health · Heather Joy Zar · 2024 · 100 citations · Cited by this paper
  6. The Pediatric Hospitalist: A Survey of What We Do and Where We Are Going · 2026 · Related
  7. Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysis · Daira Trusinska · 2025 · 33 citations · Cited by this paper
  8. Pediatric Resident Post-Rounds Communication With Families Using Languages Other Than English · 2026 · Related
  9. RSV Among American Indian and Alaska Native Children: 2019 to 2020 · Jessica E. Atwell · 2023 · 29 citations · Cited by this paper
  10. Inpatient Childhood Asthma Controller Medication Escalation and Increased Time-to-Readmission · 2026 · Related
  11. Uptake of Maternal RSV Vaccination and Infant Nirsevimab Among Infants Born October 2023 to March 2024 · Karen Blake Jacobson · 2025 · 23 citations · Cited by this paper
  12. Clinical Utility of Routine Umbilical Cord Blood Screening for ABO Incompatibility: A Single-Center Observational Study · 2026 · Related
  13. Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination — United States, October 2023–March 2024 · Ellen O'Neal Boundy · 2025 · 23 citations · Cited by this paper
  14. Racial and Ethnic Disparities in Length of Stay for Pediatric Bacterial Tracheostomy-Associated Infections · 2026 · Related
  15. Recommendations for the Prevention of RSV Disease in Infants and Children: Policy Statement · Sean T. O’Leary · 2025 · 22 citations · Cited by this paper
  16. Psychometric Evaluation of a NICU Version of the Family-Centered Care Experience Survey · 2026 · Related
  17. Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children — Yukon-Kuskokwim Delta Region, Alaska, October 2023–June 2024 · Brian Lefferts · 2024 · 21 citations · Cited by this paper
  18. Disparities in the Availability and Acceptance of Nirsevimab in Massachusetts · Claire Abraham · 2024 · 17 citations · Cited by this paper
  19. RSV immunization uptake among infants and pregnant persons — Wisconsin, October 1, 2023-March 31, 2024 · Maddie Kemp · 2025 · 16 citations · Cited by this paper
  20. Disparities in Nirsevimab Uptake Across a Pediatric Primary Care Network · Mahaa M. Ahmed · 2025 · 13 citations · Cited by this paper
  21. Vaccine Administration in Children’s Hospitals · Mersine A. Bryan · 2022 · 12 citations · Cited by this paper
  22. Viral Acute Respiratory Illnesses in Young Infants Increase the Risk of Respiratory Readmission · Michiko Toizumi · 2018 · 10 citations · Cited by this paper
  23. Interventions delivered in secondary or tertiary medical care settings to improve routine vaccination uptake in children and young people: a scoping review · Sarah Blagden · 2022 · 9 citations · Cited by this paper
  24. Factors Associated With Nirsevimab Uptake in Healthy Newborns · Elena Aragona · 2024 · 9 citations · Cited by this paper
  25. A Missed Opportunity: Evaluating Immunization Status and Barriers in Hospitalized Children · Brittany Lissinna · 2024 · 7 citations · Cited by this paper
  26. Notes from the Field: Rollout of Nirsevimab to Protect Infants and Young Children During the Respiratory Syncytial Virus Season — New York City, 2023–2024 · Melanie S. Askari · 2024 · 2 citations · Cited by this paper
  27. Equitable Access to RSV Prevention: Challenges and Opportunities With Nirsevimab's Rollout · Y. Tony Yang · 2023 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)